Dr Agarwal's Hea
Dr Agarwal's Hea Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Q1 FY27 showed strong revenue growth of 26% YoY and Ind AS EBITDA growth of 25.2% with margin improvement.
From Dr Agarwal's Hea's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each).
- Same-store sales growth (SSSG) for mature facilities (pre-FY23) was strong at 16.3%, with new centers showing even higher growth.
- Patient volume growth expected to continue, supported by technology upgrades and insurance expansion.
- Premiumization and price hikes contributed ~8% to value growth.
- Expansion of network with 60 new facilities planned for FY27 (40 surgical centers), maintaining aggressive greenfield growth.
- Increasing adoption of advanced, higher-margin surgical procedures like Femto cataract and robotic surgeries expected to boost average realization per surgery.
- Focus on deeper market penetration, especially in mature South region; North and West regions showing significant growth opportunities.
2 more points from Dr Agarwal's Hea's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dr Agarwal's Hea said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Dr. Agarwal's Healthcare continues a strong expansion strategy with a large capital investment in greenfield facilities.
- In Q1 FY27 alone, 18 new greenfield facilities were commissioned, including 1 large tertiary and 15 secondary facilities across various states.
- The company plans to add 60 new facilities in FY27, including 40 surgical centers, with 12 facilities targeted for Q2 and 30 in the latter half of the year.
- There is a strong pipeline with 30+ signed Letters of Intent (LOIs) for upcoming greenfield projects.
2 more points from Dr Agarwal's Hea's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Agarwal's Hea said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- It states a strong pipeline of greenfield projects with "30-plus signed Letters of Intent (LOIs)" already in place.
- The company plans to add 60 new facilities in FY27, including 40 surgical centers.
- Expansion plans include adding 12 facilities in Q2 and 30 in the second half of the year.
- The greenfield execution engine is described as "firing" with strong pipeline and signed agreements, indicating robust upcoming projects and orders.
Dr Agarwal's Hea — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹614 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Agarwal's Hea's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dr Agarwal's Hea and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Agarwal's Hea Q1 FY27 results?
Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Q1 FY27 showed strong revenue growth of 26% YoY and Ind AS EBITDA growth of 25.2% with margin improvement.
What is Dr Agarwal's Hea share price analysis?
Dr Agarwal's Hea currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 107.4 with a market cap of ₹15,858 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwal's Hea planning capital expenditure?
Dr.
Keep Dr Agarwal's Hea on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.